Palisade Bio Inc (PALI)
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PALI. The company is developing therapies for autoimmune, inflammatory, and fibrotic diseases, with a focus on advancing novel drug candidates through early-stage clinical testing. Its lead program is PALI-2108, a prodrug PDE4 inhibitor being studied in phase 1a/b trials for ulcerative colitis and in a phase 1a trial for fibrostenotic Crohn’s disease. Palisade Bio has also entered into collaboration and licensing arrangements with Giiant Pharma, Inc., the Regents of the University of California, and Newsoara Biopharma Co., Ltd. The company is based in Carlsbad, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PALI
|
$1.56
|
-7.6% Downside
|
Fair
|
$10.22
|
504.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
2.4x
|
589.0x
|
294.5 M
|
169.3 M
|
0.0%
|
79.7%
|
30.1
|
56.9%
|
